Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs ...
Decoy Therapeutics Inc. (DCOY) is a U.S.-based, early-stage biotechnology company working to address unmet medical needs in viral diseases. The company’s strategy centers on using machine learning and artificial intelligence together with accelerated/streamlined synthesis methods to rapidly design, engineer, and manufacture peptide-conjugate drug candidates. This computational-to-lab workflow is positioned as ...Decoy Therapeutics Inc. (DCOY) is a U.S.-based, early-stage biotechnology company working to address unmet medical needs in viral diseases. The company’s strategy centers on using machine learning and artificial intelligence together with accelerated/streamlined synthesis methods to rapidly design, engineer, and manufacture peptide-conjugate drug candidates. This computational-to-lab workflow is positioned as a differentiator, enabling Decoy to iterate faster than traditional drug discovery approaches while targeting multiple viral mechanisms.
From a product and platform perspective, Decoy is associated with its Designable Multi-Antivirals (D-MAVs) concept—engineered antivirals intended to bind or act on shared viral mechanisms rather than a single narrow target. While the provided material emphasizes preclinical/early development work, the company’s core deliverable is a pipeline of candidate medicines derived from its designable peptide-conjugate platform.
Operationally, the company’s model is typical of preclinical biotech: substantial spending in research and development, limited revenue, and ongoing needs for funding. The provided financial snapshot indicators (e.g., negative return on assets and equity, negative free cash flow and operating cash flow ratios) are consistent with a development-stage organization that invests heavily before commercialization. Because the company is early-stage and focused on R&D, cost structure is likely dominated by personnel, lab work, synthesis/chemistry operations, and computational infrastructure required for AI/ML screening and design.
In terms of scale, the company is very small (about 11 full-time employees per the dataset; other references suggest a small team size in the single digits to low double digits). That small footprint is consistent with a lean early-stage research organization and indicates that many functions may be supported through collaborations, contractors, or outsourced laboratory and analytical services.
Key leadership is provided by Frederick E. (Rick) Pierce, who is described as co-founder and CEO and has served in that leadership capacity since founding. The company’s business outlook depends on advancing candidates through preclinical development and securing the financing and partnerships necessary to progress toward clinical studies.
Overall, Decoy Therapeutics aims to build a repeatable engineering platform for antiviral medicine—combining AI-enabled designability with high-speed synthesis—to shorten development timelines and create candidate therapies with broader antiviral mechanism coverage through its D-MAV framework.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$0
—
—
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-12.5M
-124.5%
-6.7%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
—
—
—
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
—
—
—
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
—
—
—
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-4.8M
-6.7%
+6.7%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
—
—
—
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
0.0%
-100.0%
—
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.13x
+7.5%
-0.4%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
